EAU 2013 - Programme Book - YouMed

Monday
Monday, 18 March - EAU Programme
258 Programme Book
Thematic Session 11
11.00 - 12.00 Systemic therapy in urological cancers
Silver Hall - Level N2
Chair: M. De Santis, Vienna (AT)
11.00 - 11.15 State-of-the-art lecture Risk stratification integrating clinical and genomic data
A. Bjartell, Malmö (SE)
Aims and objectives
There is an urgent need for improved selection of patient for new therapies such as inhibition of androgen
signaling and angiogenesis, and for immunotherapy. Prediction models for risk stratification of recurrence
after treatment for different malignancies have become increasingly popular. Nomograms developed at
Memorial Sloan-Kettering Cancer Center, MSKCC (www.nomograms.org) and other prediction models are
frequently used today. Despite numerous publications on promising biomakers, multiplex signatures and
gene panels, only PSA in blood is routinely incorporated in prediction models. This lecture will focus on
the integration of biomarkers and genomic data with clinical characteristics today and what we can expect
tomorrow.
11.15 - 11.30 State-of-the-art lecture When is chemotherapy indicated in prostate cancer?
P. Albers, Düsseldorf (DE)
11.30 - 11.45 State-of-the-art lecture Systemic therapy for renal cell cancer
A.S. Merseburger, Hanover (DE)
Aims and objectives
Emerging from a largely cytokine-based era, the clinical development of the last decade has led to a dramatic
change in the therapeutic landscape of renal cell carcinoma. Molecularly targeted and antiangiogenic agents
now form the backbone of most therapeutic strategies for patients with advanced metastatic renal cell
carcinoma. This lecture focuses on the clinical efficacy of systemic therapy in RCC patients and gives a brief
overview on novel areas of development and emerging substances including vaccine and immunotherapies
which hold promise to improve therapeutic outcomes for patients with mRCC.
11.45 - 12.00 State-of-the-art lecture Second-line chemotherapy for urothelial cancer
M. De Santis, Vienna (AT)
Aims and objectives
Bladder cancer is a chemotherapy sensitive disease and cisplatin based combination treatment has been the
standard for many years. Only about 15% of patients experience long term remissions. For those who fail
first-line chemotherapy the prognosis usually is dismal. Second-line chemotherapy data are highly variable.
Only recently, three prognostic factors have been established, resulting in 4 prognostic groups. A reasonable
strategy in the second-line setting is to rechallenge former cisplatin sensitive patients if progression occurs
at least 6-12 months after first treatment. The only phase III trial in this context explored vinflunine plus best
supportive care (BSC) randomised against BSC alone in patients failing first-line platinum based combination
chemotherapy. The results showed a survival benefit in favour of vinflunine, which was statistically significant
in the eligible patient population. Currently, vinflunine is the only approved second-line treatment in Europe.
Recent advances and future strategies and studies will be summarised and critically discussed.